Study on Toxicity Reduction and Potency Induction in Whole-cell Pertussis Vaccine by Developing a New Optimal Inactivation Condition Processed on Bordetella pertussis
- PMID: 27679704
- PMCID: PMC5035437
- DOI: 10.5812/jjm.34153
Study on Toxicity Reduction and Potency Induction in Whole-cell Pertussis Vaccine by Developing a New Optimal Inactivation Condition Processed on Bordetella pertussis
Abstract
Background: Whooping cough is caused by Bordetella pertussis, and it remains a public health concern. Whole-cell pertussis vaccines have been commonly employed for expanded immunization. There is no doubt of the efficacy of whole cell pertussis vaccine, but it is necessary to improve the vaccine to decrease its toxicity.
Objectives: In this study, an inactivation process of dealing with pertussis bacteria is optimized in order to decrease the bacteria content in human doses of vaccines and reduce the vaccine's toxicity.
Materials and methods: The bacterial suspensions of pertussis strains 509 and 134 were divided into 21 sample parts from F1 to F21 and inactivated under different conditions. The inactivated suspensions of both strains were tested for opacity, non-viability, agglutination, purity, and sterility; the same formulation samples that passed quality tests were then pooled together. The pool of inactivated suspensions were analyzed for sterility, agglutination, opacity, specific toxicity, and potency.
Results: The harvest of both bacterial strains showed purity. The opacity of various samples were lost under different treatment conditions by heat from 8% to 12%, formaldehyde 6% to 8%, glutaraldehyde 6% to 8%, and thimerosal 5% to 8%. Tests on suspensions after inactivation and on pooled suspensions showed inactivation conditions not degraded agglutinins of both strains. The samples of F2, F4, F8, F12, F15, and F17 passed the toxicity test. The potency (ED50) of these samples showed following order F17 > F12 > F8 > F15, F4 > F2, and F17 revealed higher potency compared to other formulations.
Conclusions: It can be concluded that F17 showed desirable outcomes in the toxicity test and good immunogenicity with a low bacterial number content. Consequently, lower adverse effects and good immunogenicity are foreseeable for vaccine preparation with this method.
Keywords: Pertussis; Potency Test; Toxicity Test; Whole-Cell Vaccines; Whooping Cough.
Figures
Similar articles
-
A New Vaccine Delivery Vehicle and Adjuvant Candidate: Bordetella pertussis Inactivated Whole Cells Entrapped in Alginate Microspheres.Curr Pharm Des. 2017;23(18):2665-2672. doi: 10.2174/1381612823666170112124303. Curr Pharm Des. 2017. PMID: 28079006
-
Studies on the optimal conditions for inactivation of Bordetella pertussis organisms with glutaraldehyde for preparation of a safe and potent pertussis vaccine.Vaccine. 1988 Dec;6(6):491-6. doi: 10.1016/0264-410x(88)90099-0. Vaccine. 1988. PMID: 2907704
-
The effects of different inactivating agents on the potency, toxicity and stability of pertussis vaccine.J Biol Stand. 1987 Jan;15(1):87-98. doi: 10.1016/0092-1157(87)90020-5. J Biol Stand. 1987. PMID: 3104344
-
Feasible improvements in vaccines in the Expanded Programme on Immunization.Rev Infect Dis. 1989 May-Jun;11 Suppl 3:S530-7. doi: 10.1093/clinids/11.supplement_3.s530. Rev Infect Dis. 1989. PMID: 2669097 Review.
-
Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection.Paediatr Drugs. 2000 Mar-Apr;2(2):139-59. doi: 10.2165/00148581-200002020-00007. Paediatr Drugs. 2000. PMID: 10937466 Review.
Cited by
-
Pertussis in Early Infancy: Diagnostic Challenges, Disease Burden, and Public Health Implications Amidst the 2024 Resurgence, with Emphasis on Maternal Vaccination Strategies.Vaccines (Basel). 2025 Mar 5;13(3):276. doi: 10.3390/vaccines13030276. Vaccines (Basel). 2025. PMID: 40266155 Free PMC article. Review.
-
Evaluating the Compatibility of New Recombinant Protein Antigens (Trivalent NRRV) with a Mock Pentavalent Combination Vaccine Containing Whole-Cell Pertussis: Analytical and Formulation Challenges.Vaccines (Basel). 2024 Jun 3;12(6):609. doi: 10.3390/vaccines12060609. Vaccines (Basel). 2024. PMID: 38932338 Free PMC article.
-
Safety and efficacy of a Bordetella bronchiseptica outer membrane proteins (OMPs) subunit vaccine in a murine model.J Vet Sci. 2025 May;26(3):e39. doi: 10.4142/jvs.25018. J Vet Sci. 2025. PMID: 40461428 Free PMC article.
-
Development and Evaluation of Five-in-One Vaccine Microneedle Array Patch for Diphtheria, Tetanus, Pertussis, Hepatitis B, and Haemophilus influenzae Type b: Immunological Efficacy and Long-Term Stability.Pharmaceutics. 2024 Dec 23;16(12):1631. doi: 10.3390/pharmaceutics16121631. Pharmaceutics. 2024. PMID: 39771609 Free PMC article.
-
Bordetella bronchiseptica and Bordetella pertussis: Similarities and Differences in Infection, Immuno-Modulation, and Vaccine Considerations.Clin Microbiol Rev. 2023 Sep 21;36(3):e0016422. doi: 10.1128/cmr.00164-22. Epub 2023 Jun 12. Clin Microbiol Rev. 2023. PMID: 37306571 Free PMC article. Review.
References
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous